Literature DB >> 4213756

The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

H A Cooper, R H Wagner.   

Abstract

Factor VIII in preparations from normal plasma is a large glycoprotein of greater than 2 million molecular weight which elutes in the exclusion volume of 4% agarose gels at an ionic strength of 0.15. Recent studies have demonstrated that the factor VIII in canine and bovine plasma is a macromolecular complex composed of a large inert carrier protein and a noncovalently bound small fragment which contains the procoagulant active site. This complex is dissociable in 0.25 M CaCl(2), and conditions for its recombination have been reported. The present study reports the dissociation characteristics of normal human factor VIII preparations in 0.25 M CaCl(2) and the ability to achieve quantitative recombination of the dissociated fragments of normal human and bovine factor VIII after the removal of Ca(2+). The recombination technique was used to characterize further the defect in hemophilia and von Willebrand's disease. Void volume preparations from human hemophilia A(-), canine hemophilia A, and human von Willebrand's plasma, with no factor VIII procoagulant activity, were mixed with the small active fragment prepared from the normal plasma of their respective species. Chromatography of the three mixtures in agarose gel showed that the fractions from the human hemophilic plasmas contained a molecule that bound the small active normal fragment, but neither the fractions from canine hemophilia A plasmas nor the fractions from the human von Willebrand's plasmas demonstrated evidence of such material. These data suggest that there is present in human hemophilia A plasma a normal functional carrier molecule which is absent or nonfunctional in the plasma of hemophilic dogs and humans with von Willebrand's disease.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4213756      PMCID: PMC301657          DOI: 10.1172/JCI107853

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Plasma antihemophilic factor biological and clinical aspects.

Authors:  K M BRINKHOUS
Journal:  Sang       Date:  1954

2.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

Review 3.  Blood coagulation factor VIII (antihemophilic factor): with comments on von Willebrand's disease and Christmas disease.

Authors:  E M Barrow; J B Graham
Journal:  Physiol Rev       Date:  1974-01       Impact factor: 37.312

4.  The specificity of antibodies to factor VIII produced in the rabbit after immunization with human cryoprecipitate.

Authors:  P B Kernoff; C R Rizza
Journal:  Thromb Diath Haemorrh       Date:  1973-06-28

5.  Isolation and characterization of human Factor VIII (antihemophilic factor).

Authors:  M E Legaz; G Schmer; R B Counts; E W Davie
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

6.  Two types of haemophilia (A+ and A-): a study of 48 cases.

Authors:  K W Denson; R Biggs; M E Haddon; R Borrett; K Cobb
Journal:  Br J Haematol       Date:  1969-08       Impact factor: 6.998

7.  Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography.

Authors:  H J Weiss; L L Phillips; W Rosner
Journal:  Thromb Diath Haemorrh       Date:  1972-04-30

8.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

9.  Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities.

Authors:  T S Zimmerman; T S Edgington
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  The pathogenesis of hemophilia; an experimental analysis of the anticephalin hypothesis in hemophilic dogs.

Authors:  J B GRAHAM; E M BARROW
Journal:  J Exp Med       Date:  1957-08-01       Impact factor: 14.307

View more
  7 in total

1.  Effects of thrombin treatment of preparations of factor VIII and the Ca2+-dissociated small active fragment.

Authors:  H A Cooper; F F Reisner; M Hall; R H Wagner
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

2.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

3.  Effect of phospholipases on factor-VIII activity.

Authors:  R Ananthakrishnan; S D'Souza
Journal:  Hum Genet       Date:  1978-01-19       Impact factor: 4.132

4.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

5.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

6.  Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.